ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) announced today results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance ...

Watch a video about Steve, an Optune user. Learn how Steve manages his treatment while enjoying his favorite activities. Watch a video about Steve, an Optune user ...

As a particularly aggressive brain tumor, it almost goes without saying that glioblastomas are scary things. Fortunately, patients are benefiting from a new technology that has only been available to ...

ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its new Head Flexible Electrode (HFE) transducer arrays for use ...

(RTTNews) - Novocure (NVCR) announced the FDA approved new Head Flexible Electrode transducer arrays for use with Optune Gio for the treatment of adult patients with glioblastoma multiforme. Novocure ...

As a result, Optune users experience very little in the way of side effects. That's a highly attractive advantage when compared to other cancer treatments like chemotherapy and radiation. When ...

(RTTNews) - Novocure (NVCR) an oncology company, has received approval from the FDA for its new Head Flexible Electrode transducer arrays, designed for use with its Optune Gio device, which is used in ...